41.16

1.68% 0.68

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $41.16, with a volume of 906.36K. It is up +1.68% in the last 24 hours and up +6.91% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$40.48

Open:

$40.63

24h Volume:

906.36K

Relative Volume:

1.02

Market Cap:

$2.40B

Revenue:

$899.11M

Net Income/Loss:

$145.62M

P/E Ratio:

16.58

EPS:

2.4829

Net Cash Flow:

$322.54M

1W Performance:

-3.70%

1M Performance:

+6.91%

6M Performance:

+51.88%

1Y Performance:

+53.81%

1-Day Range:

$40.00

$41.79

1-Week Range:

$39.72

$43.27

52-Week Range:

$25.52

$43.49

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

293

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	41.16	2.40B	899.11M	145.62M	322.54M	2.4829
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Sep 24, 2026

Oppenheimer reiterates Harmony Biosciences stock rating on patent defense By Investing.com - Investing.com Canada

Sep 24, 2026

Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider

Sep 24, 2026

Sep 23, 2026